Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors (schlafen11) and immunotherapies (PD‐L1 and DLL3). The gene discussed is CD274; the disease is neoplasm.